Infection and drug resistance · 2025
β-Lactam/β-Lactamase Inhibitor Combinations Non-Susceptible ESBL-Producing Enterobacteriaceae Bloodstream Infections: An Underestimated Clinical Entity.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Yan, Ni Shuangling, Hu Hangbin, Zhang Sheng, Feng Haiting, Ni Lingmei, Chen Hongchao, Yang Qing, Yu Meihong, Qu Tingting
Аннотация
BACKGROUND: To describe the clinical and molecular characteristics of β-lactam/β-lactamase inhibitor combinations (BLBLIs) non-susceptible ESBL-producing Enterobacteriaceae (BnESBL-E) bloodstream infections (BSIs).
METHODS: A cohort study was performed with ESBL-E-BSI cases from 2017 to 2019 in East China. Clinical characteristics, risk factors, and all-course mortality were evaluated. Whole-genome sequencing and antibiotic susceptibility testing were performed.
RESULTS: Among the 187 patients with ESBL-E-BSI, 39.57% (74/187) had BnESBL-E-BSI. Nosocomial infections constituted 63.51% of BnESBL-E-BSIs, and 39.19% of cases originated from intra-abdominal sources. Risk factors for BnESBL-E-BSI included BLBLIs exposure within the preceding 3 months, ICU admission within the last 3 months, and the duration of hospital stay prior to BSI. Notably, a urinary source of bacteremia emerged as a protective factor against BnESBL-E-BSI(OR, 0.177; 95% CI, 0.049-0.647; p=0.009). BnESBL-E-BSIs were associated with a higher 28-day mortality compared to BLBLIs-susceptible cases (31.08%vs.16.81%; p=0.031). Multivariate analysis identified the Pitt bacteremia score, CRP level, and hospitalization within the preceding 3 months as risk factors for BnESBL-E-BSI-related mortality, while receipt of carbapenems within 72 hours of symptom onset improved survival(OR, 0.128; 95% CI, 0.018-0.912; p = 0.04). BnESBL-E isolates demonstrated no clonal transmission and remained highly susceptible to amikacin, carbapenems and tigecycline. Coexistence of multiple ESBL types was frequently observed, occurring in 40.6% of BnESBL-Ec and 72.7% of BnESBL-Kp isolates.
CONCLUSION: Given the high prevalence and mortality of BnESBL-E-BSI, carbapenems may be preferable treatment option for non-urinary ESBL-E-BSIs. BnESBL-E represents an underestimated clinical threat, warranting timely identification of risk factors and the consideration of appropriate empirical therapy.
METHODS: A cohort study was performed with ESBL-E-BSI cases from 2017 to 2019 in East China. Clinical characteristics, risk factors, and all-course mortality were evaluated. Whole-genome sequencing and antibiotic susceptibility testing were performed.
RESULTS: Among the 187 patients with ESBL-E-BSI, 39.57% (74/187) had BnESBL-E-BSI. Nosocomial infections constituted 63.51% of BnESBL-E-BSIs, and 39.19% of cases originated from intra-abdominal sources. Risk factors for BnESBL-E-BSI included BLBLIs exposure within the preceding 3 months, ICU admission within the last 3 months, and the duration of hospital stay prior to BSI. Notably, a urinary source of bacteremia emerged as a protective factor against BnESBL-E-BSI(OR, 0.177; 95% CI, 0.049-0.647; p=0.009). BnESBL-E-BSIs were associated with a higher 28-day mortality compared to BLBLIs-susceptible cases (31.08%vs.16.81%; p=0.031). Multivariate analysis identified the Pitt bacteremia score, CRP level, and hospitalization within the preceding 3 months as risk factors for BnESBL-E-BSI-related mortality, while receipt of carbapenems within 72 hours of symptom onset improved survival(OR, 0.128; 95% CI, 0.018-0.912; p = 0.04). BnESBL-E isolates demonstrated no clonal transmission and remained highly susceptible to amikacin, carbapenems and tigecycline. Coexistence of multiple ESBL types was frequently observed, occurring in 40.6% of BnESBL-Ec and 72.7% of BnESBL-Kp isolates.
CONCLUSION: Given the high prevalence and mortality of BnESBL-E-BSI, carbapenems may be preferable treatment option for non-urinary ESBL-E-BSIs. BnESBL-E represents an underestimated clinical threat, warranting timely identification of risk factors and the consideration of appropriate empirical therapy.